Dare Bioscience | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 2.262 K

Revenue: As of FY2025 Q3, the actual value is USD 2.262 K, missing the estimate of USD 9.75 K.

EPS: As of FY2025 Q3, the actual value is USD -0.28.

Financial Highlights for Q3 2025

Cash Position

• As of September 30, 2025, Daré Bioscience, Inc. had approximately $23.1 million in cash and cash equivalents, and working capital of approximately $3.8 million.

General and Administrative Expenses

• $2.5 million in Q3 2025 compared to $2.0 million in Q3 2024, primarily due to increases in professional services expense and commercial-readiness expenses.

Research and Development (R&D) Expenses

• $1.2 million in Q3 2025 compared to $2.7 million in Q3 2024, reflecting a decrease of 56%, mainly due to an increase in contra R&D expenses and decreases in manufacturing and personnel costs.

Loss from Operations

• Loss from operations was - $3,672,148 in Q3 2025 compared to - $4,681,349 in Q3 2024.

Net Loss

• Net loss was - $3,562,766 in Q3 2025 compared to - $4,702,501 in Q3 2024.

Comprehensive Loss

• Comprehensive loss was - $3,555,906 in Q3 2025 compared to - $4,679,566 in Q3 2024.

Loss per Common Share

• Loss per common share was - $0.28 in Q3 2025 compared to - $0.55 in Q3 2024.

Outlook / Guidance

• Daré Bioscience plans to generate revenue from DARE to PLAY™ Sildenafil Cream beginning in December 2025, while advancing a pipeline that spans both clinical innovation and near-term commercial solutions. The company expects four women’s health products to become commercially available over the next two years, supported by multiple grant-funded programs. Daré is positioned to deliver meaningful impact for women and strong value creation for shareholders.